No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 421.9x · 10Y median 17809.0x · 33rd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 19
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:01:31.280Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for Cardio Diagnostics Holdings, Inc. (CDIO) stock was $2.06 as of Oct 5, 2026, 4:00 PM EDT, up 5.10% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -54.5% · 3-year avg -40.7%/yr
Cardio Diagnostics Holdings, Inc. specializes in creating and bringing to market advanced clinical diagnostic tools that leverage epigenetic insights to address cardiovascular disease.
Biotechnology · Chicago, IL
Next Earnings Date
Nov 6, 2026
31 days away
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.97
vs Estimate
$-1.80
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CDIO | $6.10M | $2.06 | +5.10% | -54.55% | N/A | N/A | N/A |
| 2FEMY | $6.10M | $2.02 | -1.46% | -83.83% | -57.27% | N/A | vs CDIO |
| 3ENLV | $6.09M | $0.36 | -6.53% | -97.68% | -69.81% | -54.76% | vs CDIO |
| 4CUPR | $6.03M | $2.25 | -7.02% | -74.72% | N/A | N/A | vs CDIO |
| 5BMRA | $6.34M | $2.05 | -4.30% | -26.68% | -46.66% | -20.93% | vs CDIO |
| 6ENSC | $6.44M | $0.42 | +6.08% | -83.36% | -86.22% | N/A | vs CDIO |
forward FY estimate
N/A
$5360.00
vs Estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$2.06
High
N/A
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $-19.80 | $-19.80 | $-19.80 | 1 |
| Quarter ending Mar 2027 | $-2.70 | $-2.70 | $-2.70 | 1 |
| Quarter ending Jun 2027 | $-4.35 | $-4.35 | $-4.35 | 1 |
| Quarter ending Sep 2027 | $-11.70 | $-11.70 | $-11.70 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-16.50 | $-16.50 | $-16.50 | 1 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Dec 2026 | $100000.00 | $100000.00 | $100000.00 | 1 |
| Quarter ending Mar 2027 | $400000.00 | $400000.00 | $400000.00 | 1 |
| Quarter ending Jun 2027 | $7342.00 | $7342.00 | $7342.00 | 1 |
| Quarter ending Sep 2027 | $7943.00 | $7943.00 | $7943.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $25.00M | $25.00M | $25.00M | 1 |
